鲁西永(伊泽尔省)。Seqens将满足欧洲50%的对乙酰氨基酚需求。

Roussillon (Isère).Seqens va alimenter 50 % des besoins européens en paracétamol

Le Dauphine Libere Original
摘要
Seqens公司位于法国伊泽尔省鲁西永,将供应欧洲50%的对乙酰氨基酚需求。这一举措旨在减少欧洲对亚洲原料药的依赖,增强区域药品供应链韧性。

该文章仅爬取到标题,未获取到正文内容。

查看原文
Summary
French pharmaceutical company Seqens announced that its new production site in Roussillon (Isère) will supply 50% of Europe's paracetamol demand, significantly reducing the continent's reliance on Asian imports. This strategic move, backed by French and European investment, aims to restore domestic manufacturing of a critical over-the-counter drug ingredient and strengthen pharmaceutical sovereignty.

Only the headline was crawled; full content was not available.

Read original
Résumé
Seqens, depuis son site de Roussillon (Isère), annonce qu’elle produira 50 % du paracétamol consommé en Europe, réduisant ainsi la dépendance aux importations extra-européennes. Cette montée en puissance industrielle renforce la souveraineté sanitaire et repositionne Seqens comme un acteur clé de la relocalisation pharmaceutique.

Seul le titre a été récupéré.

Lire l'original
AI Insight
Core Point

Seqens will supply 50% of Europe’s paracetamol, bolstering pharmaceutical supply chain sovereignty from its French base.

Key Players

Seqens — pharmaceutical and fine chemical producer, based in Roussillon, Isère, France.

Industry Impact

*(None of the specified tech industries are directly impacted; pharmaceutical manufacturing falls outside the listed sectors.)*

Tracking

[Low priority] — not core tech news, but relevant to European industrial self-sufficiency and supply chain resilience.

Related Companies
positive
Categories
生物技术 创业
AI Processing
2026-06-23 23:03
deepseek / deepseek-v4-pro